Terms: = Ovarian cancer AND SFRP4, Q6FHJ7, 6424, ENSG00000106483, frpHE, MGC26498, FRPHE, FRP-4
18 results:
1. Short peptide domains of the Wnt inhibitor sfrp4 target ovarian cancer stem cells by neutralizing the Wnt β-catenin pathway, disrupting the interaction between β-catenin and CD24 and suppressing autophagy.
Sundaram SM; Varier L; Fathima KZ; Dharmarajan A; Warrier S
Life Sci; 2023 Mar; 316():121384. PubMed ID: 36646377
[TBL] [Abstract] [Full Text] [Related]
2. Senotherapy Protects against Cisplatin-Induced ovarian Injury by Removing Senescent Cells and Alleviating DNA Damage.
Du D; Tang X; Li Y; Gao Y; Chen R; Chen Q; Wen J; Wu T; Zhang Y; Lu H; Zhang J; Wang S
Oxid Med Cell Longev; 2022; 2022():9144644. PubMed ID: 35693700
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and sfrp4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study.
Turan H; Vitale SG; Kahramanoglu I; Della Corte L; Giampaolino P; Azemi A; Durmus S; Sal V; Tokgozoglu N; Bese T; Arvas M; Demirkiran F; Gelisgen R; Ilvan S; Uzun H
Arch Gynecol Obstet; 2022 Dec; 306(6):2105-2114. PubMed ID: 35461390
[TBL] [Abstract] [Full Text] [Related]
4. The miR-181a-sfrp4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in ovarian cancer.
Belur Nagaraj A; Knarr M; Sekhar S; Connor RS; Joseph P; Kovalenko O; Fleming A; Surti A; Nurmemmedov E; Beltrame L; Marchini S; Kahn M; DiFeo A
Cancer Res; 2021 Apr; 81(8):2044-2055. PubMed ID: 33574092
[TBL] [Abstract] [Full Text] [Related]
5. Epigenetic demethylation of sFRPs, with emphasis on sfrp4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells.
Deshmukh A; Arfuso F; Newsholme P; Dharmarajan A
Int J Biochem Cell Biol; 2019 Apr; 109():23-32. PubMed ID: 30710752
[TBL] [Abstract] [Full Text] [Related]
6. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010.
Nagase S; Ohta T; Takahashi F; Enomoto T;
J Obstet Gynaecol Res; 2019 Feb; 45(2):289-298. PubMed ID: 30426591
[TBL] [Abstract] [Full Text] [Related]
7. Finding Novel Anti-carcinomas Compounds by Targeting sfrp4 Through Molecular Modeling, Docking and Dynamic Simulation Studies.
Hassan M; Azhar M; Abbas Q; Raza H; Moustafa AA; Shahzadi S; Ashraf Z; Seo SY
Curr Comput Aided Drug Des; 2018; 14(2):160-173. PubMed ID: 29332600
[TBL] [Abstract] [Full Text] [Related]
8. Secreted Frizzled-related protein 4 (sfrp4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines.
Deshmukh A; Kumar S; Arfuso F; Newsholme P; Dharmarajan A
Sci Rep; 2017 May; 7(1):2256. PubMed ID: 28536422
[TBL] [Abstract] [Full Text] [Related]
9. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Eskander RN; Ali S; Dellinger T; Lankes HA; Randall LM; Ramirez NC; Monk BJ; Walker JL; Eisenhauer E; Hoang BH
Int J Gynecol Cancer; 2016 Jan; 26(1):125-32. PubMed ID: 26397159
[TBL] [Abstract] [Full Text] [Related]
10. Secreted frizzled-related protein 4 and its implications in cancer and apoptosis.
Pohl S; Scott R; Arfuso F; Perumal V; Dharmarajan A
Tumour Biol; 2015 Jan; 36(1):143-52. PubMed ID: 25501511
[TBL] [Abstract] [Full Text] [Related]
11. Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours.
Szala A; Sawicki S; Swierzko AS; Szemraj J; Sniadecki M; Michalski M; Kaluzynski A; Lukasiewicz J; Maciejewska A; Wydra D; Kilpatrick DC; Matsushita M; Cedzynski M
Cancer Immunol Immunother; 2013 Aug; 62(8):1411-9. PubMed ID: 23744477
[TBL] [Abstract] [Full Text] [Related]
12. The Wnt gatekeeper sfrp4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
[TBL] [Abstract] [Full Text] [Related]
13. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
Fotopoulou C; Savvatis K; Kosian P; Braicu IE; Papanikolaou G; Pietzner K; Schmidt SC; Sehouli J
Br J Cancer; 2013 Jan; 108(1):32-8. PubMed ID: 23321509
[TBL] [Abstract] [Full Text] [Related]
14. Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.
Saran U; Arfuso F; Zeps N; Dharmarajan A
BMC Cell Biol; 2012 Oct; 13():25. PubMed ID: 23039795
[TBL] [Abstract] [Full Text] [Related]
15. Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.
Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry JP; Guertler R; Hornung D; Mueller R; Fink DA; Hacker NF; Heinzelmann-Schwarz VA
PLoS One; 2012; 7(2):e31885. PubMed ID: 22363760
[TBL] [Abstract] [Full Text] [Related]
16. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.
Schlumbrecht MP; Xie SS; Shipley GL; Urbauer DL; Broaddus RR
Mod Pathol; 2011 Mar; 24(3):453-62. PubMed ID: 21102415
[TBL] [Abstract] [Full Text] [Related]
17. Expression of secreted frizzled-related protein 4 (sfrp4) in primary serous ovarian tumours.
Drake J; Shearwood AM; White J; Friis R; Zeps N; Charles A; Dharmarajan A
Eur J Gynaecol Oncol; 2009; 30(2):133-41. PubMed ID: 19480240
[TBL] [Abstract] [Full Text] [Related]
18. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
Risinger JI; Maxwell GL; Chandramouli GV; Aprelikova O; Litzi T; Umar A; Berchuck A; Barrett JC
Cancer Res; 2005 Jun; 65(12):5031-7. PubMed ID: 15958545
[TBL] [Abstract] [Full Text] [Related]
